Global News

BioLineRx acquires Agalimmune to accelerate immuno-oncology pipeline

Thursday, March 23, 2017

BioLineRx, a clinical-stage biopharmaceutical company focused on oncology and immunology, has acquired Agalimmune, a private U.K.-based company with an innovative, anti-cancer immunotherapy platform. Acquisition consideration consisted of a $6 million upfront payment, of which $3 million is in cash and the remainder in BioLineRx shares. Additional future payments may be made based on development and commercial milestones.

[Read More]

PPD launches apprenticeship for Clinical Research Associates

Thursday, March 23, 2017

Pharmaceutical Product Development (PPD) launched a clinical research associates (CRAs) apprenticeship program targeted to military veterans and military service members with medical backgrounds who are transitioning to the civilian workforce. PPD’s initiative, the first CRA apprenticeship program registered with the U.S. Department of Labor, will begin in North Carolina, Texas and California in the first quarter of this year.

[Read More]

Califf launches People-Centered Clinical Research Foundation

Wednesday, March 22, 2017

Dr. Robert Califf has launched the People-Centered Clinical Research Foundation (PCRF), a new nonprofit organization committed to accelerating people-driven research. PCRF has been created to sustain and expand a national network for clinical research that originated with funding from the Patient-Centered Outcomes Research Institute (PCORI) and studies conducted by the National Patient-Centered Clinical Research Network (PCORnet).

[Read More]

SCIEX, Children’s Medical Research Institute open ProCan to advance precision medicine

Tuesday, March 21, 2017

SCIEX, a life science analytical technologies provider, has announced that Children’s Medical Research Institute (CMRI) has opened ProCan, the Australian Cancer Research Foundation International Centre for the Proteome of Human Cancer. The Centre has been set up through an alliance with SCIEX and will enable large-scale proteome studies that will advance cancer research and ultimately aid in the promise of precision medicine.

[Read More]

Pierre Fabre, H-Immune partner to develop cancer immunotherapies

Tuesday, March 21, 2017

Pierre Fabre, a privately held pharmaceutical company in France, and H-Immune, an emerging biotechnology company focused on developing first in class immunotherapies for treatment of various cancers, have entered into a strategic research partnership which will utilize H-Immune’s unique technology platform to generate lead candidates of fully human antibodies to serve as the initial step in a program to develop immuno-oncology therapeutics.

[Read More]

PTC, OSIsoft to accelerate industrial internet of things solution development

Tuesday, March 21, 2017

PTC and OSIsoft announced their intention to integrate the ThingWorx Industrial Internet of Things (IoT) Platform with the OSIsoft PI System to enable faster development of IoT solutions from connected data sources. As planned, the integration would allow customers using the OSIsoft PI System data infrastructure to easily incorporate capabilities from ThingWorx—including application enablement, machine learning, industrial connectivity, and augmented reality—and access to applications on the ThingWorx Marketplace to more rapidly advance IoT initiatives and enable customers to expand and accelerate their return on investment.

[Read More]

Thermo Fisher Scientific, Cell and Gene Therapy Catapult collaborate

Tuesday, March 21, 2017

To help address the challenges surrounding supply chain management for cell and gene therapy around the globe, Thermo Fisher Scientific announced a collaboration with the Cell and Gene Therapy Catapult (CGT Catapult) to provide developers with both the manufacturing capability and distribution, logistics and storage capacity needed to create a seamless supply chain to accelerate cell and gene therapy development and commercialization.

[Read More]

X-Chem, Ono partner for drug discovery collaboration

Tuesday, March 21, 2017

X-Chem, a privately held biotechnology company applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, partnered with Ono Pharmaceutical. Under the terms of the agreement, X-Chem will apply its proprietary DEXTM libraries, which contain over 120 billion small molecules, toward the discovery of new drug leads against multiple promising, high-impact oncology targets.

[Read More]